The regulation of mobile medical applications

Abstract

The rapidly expanding number of mobile medical applications have the potential to transform the patient-healthcare provider relationship by improving the turnaround time and reducing costs. In September 2013, the U.S. Food and Drug Administration (FDA) issued guidance to regulate these applications and protect consumers by minimising the risks associated with their unintended use. This guidance distinguishes between the subset of mobile medical apps which may be subject to regulation and those that are not. The marketing claims of the application determine the intent. Areas of concern include compliance with regular updates of the operating systems and of the mobile medical apps themselves. In this article, we explain the essence of this FDA guidance by providing examples and evaluating the impact on academia, industry and other key stakeholders, such as patients and clinicians. Our assessment indicates that awareness and incorporation of the guidelines into product development can hasten the commercialisation and market entry process. Furthermore, potential obstacles have been discussed and directions for future development suggested.

Threats and thrills: pregnancy apps, risk and consumption

“…As is the case with other medical and health apps, the monitoring and regulation of pregnancy apps, given their proliferation, remains a challenge for regulatory bodies (Yetisen et al, 2014). The UK Government has released guidance on apps and other standalone medical devices under the policy of 'patient safety' (MHRA 2014).…”

A molecularly imprinted polymer based a lab-on-paper chemiluminescence device for the detection of dichlorvos

“…It will be useful in contexts where scientific equipment and trained personnel are in short supply. Smartphone technology [35] including colorimetric tests [36] can be transformative to the deployment of lab-on-chip diagnostics [37]. The devices integration with a camera phone have increased remarkably in recent years and will no doubt continue to do so for the foreseeable future.…”

Usability, Acceptability, and Usefulness of an mHealth App for Diagnosing and Monitoring Patients With Breakthrough Cancer Pain (Preprint)

“…With the rise of smartphone usage in the medical space, in 2013, the FDA issued to regulate mobile medical applications and protect users from their unintended use, soon followed by European and other regulatory agencies [13]. App INES·DIO is certified as a CE-mark Class-1 medical device used to produce and/or change data of an individual cancer patient with the aim of a better management and control of the irruptive pain.…”